Allurion Technologies Inc. Earnings Recaps
Q3 2025
Nov 12, 2025
Allurion Technologies reported third-quarter revenues of $2.7 million, reflecting a strategic shift in focus to a comprehensive obesity management strategy. The company successfully passed several key FDA inspection milestones, signaling progress towards the approval of their Smart Capsule.
Key takeaways
- Revenue of $2.7 million was impacted by a strategic restructuring to enhance focus on customer accounts promoting combined treatments with GLP-1s.
- Operating expenses decreased by 29% year-over-year to $10.9 million, resulting in a narrowed operating loss of $9.6 million, down 22% from the previous year.
- The restructuring aims to position Allurion for long-term growth, particularly as they anticipate new patient influx from patients discontinuing GLP-1 treatments.
- Allurion is transitioning towards a debt-free structure, exchanging outstanding debt for convertible equity while securing additional financing to strengthen its balance sheet.
- The company is exploring innovative R&D initiatives, including a drug-eluting balloon in collaboration with a strategic partner, potentially revolutionizing obesity therapy.
Q2 2025
Aug 13, 2025
Allurion Technologies reported a transformative second quarter, highlighting strategic pivots towards innovative obesity care solutions and a strong performance in key growth accounts.
Key takeaways
- Transitioned distribution strategy to focus on partners promoting comprehensive obesity management, resulting in a 20% growth in targeted accounts.
- Initiated development of a novel GLP-1 drug-eluting intragastric balloon, addressing adherence issues and enhancing treatment efficacy.
- Submitted the final module of the PMA application on schedule, demonstrating significant weight loss efficacy exceeding preset target margins.
- Resized sales force to prioritize high-performing accounts, positioning for long-term growth potential outside the U.S. market.
- Launched a multicenter study in Europe to validate combination therapy's impact on weight loss and GLP-1 adherence, with enrollment expected by year-end.